Q1 2025 KORU Medical Systems Inc Earnings Call Transcript
Key Points
- KORU Medical Systems Inc (KRMD) reported a record revenue of $9.6 million for Q1 2025, marking an 18% increase over the prior year.
- The company achieved a gross margin of 62.8%, a 50 basis point improvement compared to the same period last year.
- International revenue grew by 36%, driven by patient growth and new distributor relationships in the Middle East and North Africa.
- KORU Medical Systems Inc (KRMD) plans to submit two additional commercialized drugs for 510(k) clearance by the end of 2025, expanding their pipeline.
- The company raised its 2025 revenue guidance to a range of $38.5 million to $39.5 million, representing a 15% to 17% year-over-year growth.
- Pharma Services and Clinical Trials revenues declined by 39% over the prior year due to lower clinical trial orders.
- The international business may experience uneven quarterly revenues due to distributor stocking, impacting Q2 numbers.
- Tariff-related pressures are expected to impact gross margins, with an estimated 100 basis point effect included in the guidance.
- The company faces challenges in expanding its presence in historically e-pump dominated markets.
- There is uncertainty regarding the full commercial potential of new drugs being pursued independently without pharma partners.
Greetings, and welcome to KORU Medical Systems first-quarter 2025 earnings conference call. (Operator Instructions)
As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Ms. Louisa Smith, Investor Relations. Thank you, Ms. Smith. You may begin.
Thank you, and good afternoon, everyone. Joining me on the call today are Linda Tharby, President and CEO of KORU Medical Systems; and Thomas Adams, Chief Financial Officer. Earlier today, KORU released financial results for the first quarter ended March 31, 2025. A copy of the press release is available on the company's website. I encourage listeners to have our press release in front of you, which includes our financial results as well as commentary on the quarter.
Additionally, we will use slides to support further commentary in today's call, which are also available on the Investor Relations section of our website. During this call, we will make certain forward-looking statements regarding
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
